RARE DISEASERESEARCH ATLAS

ORPHA:75567

Primary progressive freezing gait

medium confidenceDisorder

Also known as: PPFG

Publications

47

40th percentile

Trials

0

Interventional, condition-specific

Researchers

256

Distinct authors in sample

Gene link

Readiness

1/6

Stages with a signal

Clinical definition (Orphanet)

Primary freezing gait is a rare, heterogeneous, progressively incapacitating neurodegenerative disease characterized by freezing of gait (usually during the first 3 years), later associating postural instability, eventually resulting in a wheelchair-bound state. Other features may include mild bradykinesia, rigidity, postural tremor, hyperreflexia, speech disorder and dementia. The disease is unresponsive to dopaminergic treatments.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

1/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    47 matched papers (24 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

47

47 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

47 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

24 in the last 10 years · medium confidence · 40th percentile (publications denominator)

Phrase hits: 47 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

256

Distinct author names in 47 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Factor SA4 papers · 2023

    Department of Neurology, Emory University School of Medicine, Atlanta, Georgia 30329, USA. sfactor@emory.edu

    Papers in Europe PMC
  2. 02
    Fasano A3 papers · 2025

    Istituto di Neurologia, Università Cattolica del Sacro Cuore, Roma, Italy.

    Papers in Europe PMC
  3. 03
    Cao X2 papers · 2024

    Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

    Papers in Europe PMC
  4. 04
    Gan C2 papers · 2024

    Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

    Papers in Europe PMC
  5. 05
    Glass GA2 papers · 2010
    Papers in Europe PMC
  6. 06
    Ji M2 papers · 2024

    Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

    Papers in Europe PMC
  7. 07
    Lee MS2 papers · 2012

    Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

    Papers in Europe PMC
  8. 08
    Litvan I2 papers · 2019

    UC San Diego Department of Neurosciences, Parkinson and Other Movement Disorder Center, La Jolla, CA, United States.

    Papers in Europe PMC
  9. 09
    Morgante F2 papers · 2012

    Dipartimento di Neuroscienze, Scienze Psichiatriche ed Anestesiologiche, Università di Messina, UOC Neurologia e malattie neuromuscolari, AOU G Martino, 98125 Messina, Italy. fmorgante@gmail.com

    Papers in Europe PMC
  10. 10
    Ostrem JL2 papers · 2010

    Department of Neurology, University of California San Francisco, Center for the Surgical Treatment of Movement Disorders, San Francisco, CA 94143, USA. jill.ostrem@ucsf.edu

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Primary progressive freezing gait"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Primary progressive freezing gait"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: PPFG

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T01:50:48.503Z